Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

The treatment combination is effective and generally safe for lung cancer.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

New treatments for lupus show promise, but more research is needed, especially for children.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.